Christopher graybill joins arca as vice president, clinical development

Westminster, colo., may 05, 2021 (globe newswire) -- arca biopharma, inc. (nasdaq: abio), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that christopher graybill, ph.d., has joined arca as vice president, clinical development.
ABIO Ratings Summary
ABIO Quant Ranking